Literature DB >> 22948141

An engineered disulfide bond reversibly traps the IgE-Fc3-4 in a closed, nonreceptor binding conformation.

Beth A Wurzburg1, Beomkyu Kim, Svetlana S Tarchevskaya, Alexander Eggel, Monique Vogel, Theodore S Jardetzky.   

Abstract

IgE antibodies interact with the high affinity IgE Fc receptor, FcεRI, and activate inflammatory pathways associated with the allergic response. The IgE-Fc region, comprising the C-terminal domains of the IgE heavy chain, binds FcεRI and can adopt different conformations ranging from a closed form incompatible with receptor binding to an open, receptor-bound state. A number of intermediate states are also observed in different IgE-Fc crystal forms. To further explore this apparent IgE-Fc conformational flexibility and to potentially trap a closed, inactive state, we generated a series of disulfide bond mutants. Here we describe the structure and biochemical properties of an IgE-Fc mutant that is trapped in the closed, non-receptor binding state via an engineered disulfide at residue 335 (Cys-335). Reduction of the disulfide at Cys-335 restores the ability of IgE-Fc to bind to its high affinity receptor, FcεRIα. The structure of the Cys-335 mutant shows that its conformation is within the range of previously observed, closed form IgE-Fc structures and that it retains the hydrophobic pocket found in the hinge region of the closed conformation. Locking the IgE-Fc into the closed state with the Cys-335 mutation does not affect binding of two other IgE-Fc ligands, omalizumab and DARPin E2_79, demonstrating selective blocking of the high affinity receptor binding.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948141      PMCID: PMC3476292          DOI: 10.1074/jbc.M112.407502

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Signalling through the high-affinity IgE receptor Fc epsilonRI.

Authors:  H Turner; J P Kinet
Journal:  Nature       Date:  1999-11-25       Impact factor: 49.962

2.  Structure of the human IgE-Fc C epsilon 3-C epsilon 4 reveals conformational flexibility in the antibody effector domains.

Authors:  B A Wurzburg; S C Garman; T S Jardetzky
Journal:  Immunity       Date:  2000-09       Impact factor: 31.745

3.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

4.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

5.  Version 1.2 of the Crystallography and NMR system.

Authors:  Axel T Brunger
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

6.  The analysis of the human high affinity IgE receptor Fc epsilon Ri alpha from multiple crystal forms.

Authors:  S C Garman; S Sechi; J P Kinet; T S Jardetzky
Journal:  J Mol Biol       Date:  2001-08-31       Impact factor: 5.469

Review 7.  Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.

Authors:  Charles E Owen
Journal:  Pharmacol Ther       Date:  2006-09-25       Impact factor: 12.310

8.  The crystal structure of IgE Fc reveals an asymmetrically bent conformation.

Authors:  Tommy Wan; Rebecca L Beavil; Stella M Fabiane; Andrew J Beavil; Maninder K Sohi; Maura Keown; Robert J Young; Alistair J Henry; Ray J Owens; Hannah J Gould; Brian J Sutton
Journal:  Nat Immunol       Date:  2002-06-17       Impact factor: 25.606

9.  Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI.

Authors:  Mary D Holdom; Anna M Davies; Joanne E Nettleship; Sarah C Bagby; Balvinder Dhaliwal; Enrico Girardi; James Hunt; Hannah J Gould; Andrew J Beavil; James M McDonnell; Ray J Owens; Brian J Sutton
Journal:  Nat Struct Mol Biol       Date:  2011-04-24       Impact factor: 15.369

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  6 in total

1.  Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions.

Authors:  Luke F Pennington; Pascal Gasser; Daniel Brigger; Pascal Guntern; Alexander Eggel; Theodore S Jardetzky
Journal:  J Allergy Clin Immunol       Date:  2021-05-12       Impact factor: 14.290

2.  Structural and Physical Basis for Anti-IgE Therapy.

Authors:  Jon D Wright; Hsing-Mao Chu; Chun-Hsiang Huang; Che Ma; Tse Wen Chang; Carmay Lim
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

3.  Thermal sensitivity and flexibility of the Cε3 domains in immunoglobulin E.

Authors:  Katy A Doré; Anna M Davies; Nyssa Drinkwater; Andrew J Beavil; James M McDonnell; Brian J Sutton
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-08-24       Impact factor: 3.036

4.  Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody.

Authors:  Jiun-Bo Chen; Faruk Ramadani; Marie O Y Pang; Rebecca L Beavil; Mary D Holdom; Alkistis N Mitropoulou; Andrew J Beavil; Hannah J Gould; Tse Wen Chang; Brian J Sutton; James M McDonnell; Anna M Davies
Journal:  Sci Rep       Date:  2018-08-01       Impact factor: 4.996

5.  Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex.

Authors:  Luke F Pennington; Pascal Gasser; Silke Kleinboelting; Chensong Zhang; Georgios Skiniotis; Alexander Eggel; Theodore S Jardetzky
Journal:  Nat Commun       Date:  2021-12-03       Impact factor: 14.919

6.  Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.

Authors:  Luke F Pennington; Svetlana Tarchevskaya; Daniel Brigger; Karthik Sathiyamoorthy; Michelle T Graham; Kari Christine Nadeau; Alexander Eggel; Theodore S Jardetzky
Journal:  Nat Commun       Date:  2016-05-19       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.